🔎 Trials Near Me

Utama › Neuropati Sensori dan Autonomi Hereditari › Virginia

Kajian klinikal Neuropati Sensori dan Autonomi Hereditari di Virginia

7 kajian untuk Neuropati Sensori dan Autonomi Hereditari sedang mencari peserta di lokasi di Virginia.

Bandar di Virginia

Teks kajian rasmi (Bahasa Inggeris)

Study of ACR-2316 in Specific Advanced Solid Tumors

  • Next Virginia, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06667141

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07749586

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Virginia Cancer Specialists, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • USO-Virginia Cancer Specialists, PC, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT05768139

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • NEXT, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT06993844

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  • Virginia Cancer Specialists, Fairfax
Mengambil pesertaFasa 1
Umur 18 ke atas · Wanita · Dikemas kini 22 Apr 2026 · NCT05683418

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

  • Virginia Cancer Specialists, P.C., Fairfax
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 24 Dis 2025 · NCT06463028

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.